REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Feb 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-02-01

Reporting Person: RYAN ARTHUR F (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-01	Common Stock	S	9	$504.68	Disposed	23782	Direct
2021-02-01	Common Stock	S	17	$505.6	Disposed	23765	Direct
2021-02-01	Common Stock	S	30	$506.44	Disposed	23735	Direct
2021-02-01	Common Stock	S	22	$507.39	Disposed	23713	Direct
2021-02-01	Common Stock	S	16	$508.52	Disposed	23697	Direct
2021-02-01	Common Stock	S	4	$509.28	Disposed	23693	Direct
2021-02-01	Common Stock	S	2	$512.82	Disposed	23691	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 9 shares of Company stock on February 1, 2021 at prices ranging from $504.32 to $504.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.

F3: Represents volume-weighted average price of sales of 17 shares of Company stock on February 1, 2021 at prices ranging from $505.14 to $505.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.

F4: Represents volume-weighted average price of sales of 30 shares of Company stock on February 1, 2021 at prices ranging from $506.00 to $506.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.

F5: Represents volume-weighted average price of sales of 22 shares of Company stock on February 1, 2021 at prices ranging from $507.00 to $507.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.

F6: Represents volume-weighted average price of sales of 16 shares of Company stock on February 1, 2021 at prices ranging from $508.01 to $508.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.

F7: Represents volume-weighted average price of sales of 4 shares of Company stock on February 1, 2021 at prices ranging from $509.14 to $509.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.